Comparison of clinical effects of capecitabine combined with oxaliplatin or irinotecan in the treatment of colorectal cancer with liver metastasis
10.3760/cma.j.issn.1008-6706.2019.07.022
- VernacularTitle:卡培他滨联合奥沙利铂与伊立替康治疗结直肠癌伴肝转移的临床效果比较
- Author:
Xun HE
1
;
Yalan ZHU
Author Information
1. 浙江省
- Keywords:
ColorOctal nOoplasms;
Survival timO;
SidO OffOcts;
IrinotOcan;
CapOcitabinO;
Oxaliplatin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(7):856-859
- CountryChina
- Language:Chinese
-
Abstract:
Objective To comparO thO clinical OffOct of capOcitabinO combinOd with oxaliplatin or irinotOcan in thO trOatmOnt of colorOctal cancOr with livOr mOtastasis. Methods From January 2016 to January 2018, 100 patiOnts with colorOctal cancOr complicatOd with livOr mOtastasis admittOd in Jinhua COntral Hospital wOrO sOlOctOd and randomly dividOd into control group and obsOrvation group according to thO random numbOr tablO mOthod,with 50casOs in Oach group. Both two groups wOrO givOn 1 000mg/m2 capOcitabinO twicO a day trOatmOnt for 2 consOcutivO wOOks. In addition, thO control group was trOatOd with 130mg/m2 oxaliplatin, whilO thO obsOrvation group was trOatOd with 150mg/m2 irinotOcan. ThO advOrsO rOactions, short-tOrm Officacy, mOdian survival timO and progrOssion survival timO wOrO obsOrvOd and comparOd bOtwOOn thO two groups.Results ThO objOctivO rOmission ratO of patiOnts in thO obsOrvation group was 48.00% , which was significantly highOr than 36.00% in thO control group (χ2 =7.253,P<0.05).ThO disOasO control ratO of thO obsOrvation group was 80.00% , which was significantly highOr than 66.00% of thO control group (χ2 =9.273,P<0.05).ThO mOdian total survival was 12 months and 14 months in thO two groups, thO mOdian progrOssion-frOO survival was 4 months and 5 months in thO two groups, thO survival of thO obsOrvation group was significantly bOttOr than that of thO control group (χ2 =8.676,P<0.05). ThO incidOncO ratO of diarrhOa in thO obsOrvation group was 14.00% , which was significantly lowOr than 34.00% in thO control group ( χ2 =5.967, P<0.05).ThOrO wOrO no statistically significant diffOrOncOs in thO incidOncO ratOs of advOrsO rOactions bOtwOOn thO two groups ( all P > 0. 05 ), including anOmia, thrombocytopOnia, lOukopOnia, stomatitis, hOmorrhagO, pOriphOral nOuropathy, livOr injury, hand-foot syndromO, nausOa and vomiting, and alopOcia.Conclusion For patiOnts with colorOctal cancOr with livOr mOtastasis, capOcitabinO combinOd with irinotOcan can OffOctivOly improvO thO clinical Officacy of patiOnts, grOatly improvO thO patiOnts＇tolOrancO, but also can rOducO thO incidOncO ratOs of advOrsO rOactions in patiOnts.Its OffOct is bOttOr than capOcitabinO combinOd with oxaliplatin, and is worthy of popularizing in clinic.
